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Abstract
Background: 454 sequencing is currently the method of choice for sequencing of antibody repertoires and libraries
containing large numbers (10
6 to 10
12) of different molecules with similar frameworks and variable regions which poses
significant challenges for identifying sequencing errors. Identification and correction of sequencing errors in such
mixtures is especially important for the exploration of complex maturation pathways and identification of putative
germline predecessors of highly somatically mutated antibodies. To quantify and correct errors incorporated in 454
antibody sequencing, we sequenced six antibodies at different known concentrations twice over and compared them
with the corresponding known sequences as determined by standard Sanger sequencing.
Results: We found that 454 antibody sequencing could lead to approximately 20% incorrect reads due to
insertions that were mostly found at shorter homopolymer regions of 2-3 nucleotide length, and less so by
insertions, deletions and other variants at random sites. Correction of errors might reduce this population of
erroneous reads down to 5-10%. However, there are a certain number of errors accounting for 4-8% of the total
reads that could not be corrected unless several repeated sequencing is performed, although this may not be
possible for large diverse libraries and repertoires including complete sets of antibodies (antibodyomes).
Conclusions: The experimental test procedure carried out for assessing 454 antibody sequencing errors reveals
high (up to 20%) incorrect reads; the errors can be reduced down to 5-10% but not less which suggests the use of
caution to avoid false discovery of antibody variants and diversity.
Background
The high-throughput 454 sequencing method has been
applied for antibodies but errors associated with antibody
repertoires and libraries are unknown and not yet quanti-
fied. Recently, antibodies from normal humans and
patients have been sequenced and analyzed for identify-
ing usage of different allelic genes, mutations and clonal
expansions to help further our understanding of immune
repertoire and clinical applications [1-3]. The extremely
sensitive relationship between antibody sequence and
function requires more accurate 454 sequencing. Antibo-
dies have similar frameworks interspersed with highly
variable regions and are formed by the recombination of
two or three different genes, VJ for light and VDJ for
heavy chains. Consequently, the available error correcting
methods and algorithms developed for high-throughput
sequence data [4-6] may not be relevant to 454 antibody
sequencing. Although potential errors due to single
nucleotide substitution and small InDels, insertion and
deletion, associated with 454 pyrosequencing are known
[7], exact error quantification and measurement of preci-
sion is not possible without conducting repeat sequen-
cing runs of known antibody sequence target. Therefore,
we performed 454 sequence analyses of six different anti-
bodies at varied concentrations twice over and compared
the reads with the original sequences determined by stan-
dard Sanger sequencing. This allowed us to identify the
types of errors and estimate error rates, and suggest cor-
rections applicable to 454 antibody sequencing for better
confidence in the assessment of data quality.
Results and Discussion
The antibodyome approach through 454 sequencing in
exploring complex maturation pathways and identification
of putative germline predecessors of highly somatically
* Correspondence: dimiter.dimitrov@nih.gov
† Contributed equally
1Protein Interactions Group, Center for Cancer Research Nanobiology
Program, National Cancer Institute (NCI)-Frederick, National Institutes of
Health (NIH), Frederick, MD 21702-1201, USA
Full list of author information is available at the end of the article
Prabakaran et al. BMC Research Notes 2011, 4:404
http://www.biomedcentral.com/1756-0500/4/404
© 2011 Dimitrov et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.mutated antibodies could be useful in the development of
effective vaccines against diseases such as AIDS and
cancer [8]. Identification and correction of errors in 454
antibody sequencing is therefore of critical importance. To
characterize and correct the 454 antibody sequencing
errors, we performed the 454 sequencing of six clonally-
related antibodies of known sequences at different concen-
trations twice over and calculated the error rates by com-
paring them to the results obtained from standard Sanger
sequencing. The number of sequences produced was
found to be correlated with the estimated number of mole-
cules based on the content of DNA and concentration
(Table 1). Sample antibody #1 has the highest occurrence
of sequences and results of its duplicate sequencing were
used to assess sequence quality from the two independent
runs. The high-throughput 454 sequence data obtained for
the six antibodies were compared with their known
sequences using the pair-wise sequence comparison by the
BLAST method. This helped us to identify accurate reads
as well as erroneous reads where we observed different
types of errors and their frequencies such as point muta-
tion due to insertion, deletion or substitution, and errors
involving two or more than two nucleotides (see additional
file 1 for error characterization; types of errors and their
f r e q u e n c i e sa sf o u n di na n t i b o d i e s# 1 - 6 ) .T h e s er e s u l t sp r o -
vided an assessment of types and frequencies of errors
observed in 454 antibody sequencing of six antibodies #1-6
which were 3-fold serially diluted.
Our analysis revealed the different types of errors that
could be incorporated during the 454 antibody sequen-
cing. Antibodies #5 and #6 were not represented by a suf-
ficient number of sequences to carry out a robust
statistical analysis. Of the four antibodies #1-4, as depicted
in Figure 1, we found that up to 60% of sequences as accu-
rate reads and the remaining 40% had different types of
sequence errors involving point mutations - insertion,
deletion and substitution, and mixed error types involving
more than 2 nucleotide changes. These data suggested
that the amount of DNA used for the 454 sequencing did
not significantly affect the observed errors. We further
analyzed in detail the results from the two repeat runs of
antibody #1 for more reliable statistics in computing the
frequencies of different types of errors among erroneous
reads. The single base-pair insertion was found to be the
major cause of errors in ~12% of the total sequence reads
from each data set which further increased to ~20% in
combination with errors due to 2 or more insertions. Of
the other types of point mutations, deletion and single
substitution together accounted for 10% of errors while
the errors due to variations with more than 2 nucleotides
accounted for the remaining ~10%.
To examine the consequence of these sequence errors,
we performed IMGT/HighV-QUEST analysis of
sequences for Run 1 and 2, and the results were summar-
ized in Table 2. Most of the errors caused frameshifts,
stop codons and unproductive rearrangements, resulting
in functionally unproductive antibodies in more than 30%
of the total reads. Also, we could identify, locate and cor-
rect errors in the V-region introduced by insertions and
deletions using the IMGT/HighV-QUEST analysis tool.
This error correction process using the IMGT tool could
able to recover 16% and 23% of the sequence data from
Run 1 and 2, respectively. The distribution of insertion
errors along the V regions, frameworks (FR1-3) and com-
plementarity determining regions (CDR1 and 2), of the
antibodies indicated that sequence data from Run 2 had
almost double the insertion errors at the CDR1 than from
Run 1 (Figure 2a). This type of asymmetric incorporation
of errors appeared in the repeated sequencing that was
previously reported for another sequencing platform [6].
Further, to determine whether any specific types of errors
observed were common among the two runs of antibody
#1 as well as in others, we analyzed the specific locations
and types of nucleotides involved in the insertion and
deletion errors. We found that the nucleotide G, C and A
were consistently inserted causing sequencing errors as
shown for the runs 1 and 2 of antibody #1 (Figure 2b). We
observed more than 50% of insertion with G and mainly
occur at the site of polyG residues. Specifically, we found
the most common errors which occurred due to insertions
at either codon positions 27 and 29 of CDR1 regions
through insertion of “G” and “A”, respectively, in both the
4 5 4d a t as e t so fr u n s 1a n d2f o ra n t i b o d y# 1 .T h e s et w o
specific insertion errors occurred at polyG hotspots
accounted for 30% in the run 1 and 50% in the run 2. We
noted similar observation of errors but occurred at differ-
ent sites of polyG as well as polyC, polyA and polyT in
multiple reads, as shown for an example from the run #1
of antibody #1 (Table 3). This indicated that most of the
insertions and deletions could even occur at relatively
shorter homopolymer regions of 2-4 nucleotide length.
Further, these errors were found to be distributed across
the V-D-J regions (See additional file 2). We noted several
errors due to insertion and deletion at the homopolymeric
Table 1 454 sequencing of six different antibodies at
different concentrations (3-fold dilution) produced
different number of sequences (number in parentheses
denotes the results from the second run)
Control
antibodies
Number of
molecules
Number of 454
sequences
1 100 1567 (1337)
2 33 352
3 11 159
44 3 9
51 8
6 0.4 5
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Generally, these types of positional dependent insertion or
deletion errors at homopolymeric regions in the antibody
sequences can be detected and corrected as most of the
errors led to frameshifts modifying the conserved cysteines
and tryptophan residues. However, we observed that only
8% of sequences in run 1 and 2% in run 2 of antibody #1
did not cause frameshifting and led to altered nucleotide
sequences. But, those altered reads could be still identified
by IMGT tool which compares the user sequences with
germline V genes to find the presence of insertion or dele-
tion. Only errors in the CDR3 regions that do not cause
any frameshifting and lacks significant identities to the D
genes would be challenging for 454 antibody sequencing.
We performed nucleotide composition analysis of 454
sequences to find out whether any significant preference
among nucleotides does exist for the observed point
mutations. We noted some preferences for certain type
of nucleotides either alone or in combination with others
found inserted, deleted or substituted recurrently in
more than 0.5% of erroneous sequences from Run 1 and
2 (Figure 3). For example, we noted a single nucleotide
“G” was inserted (dA = 0, dG = 1, dT = 0 and dC = 0,
shown at position 1 of the horizontal axis) in 7% and 10%
of the sequences from Run 1 and 2, respectively, which
was found to be appeared at the conserved codon posi-
tion 27 as found by the IMGT/HighV-QUEST. The other
recurring erroneous sequences ranged from 0.5% to 3%
which also had specific usage of particular nucleotides.
Importantly, we found that the errors caused by single
nucleotide substitution were difficult to identify and
there could be a limitation for the error corrections. To
locate these errors, we performed multiple sequence
alignment of erroneous sequences with single substitu-
tion errors, which indicated that these errors distributed
stochastically along the frameworks and CDR regions,
up to 4% and 8% for Run 1 and 2, respectively. The dis-
tribution of these substitution errors are shown in addi-
tional file 3. Most of these single substitutions resulted
in replacement mutations and therefore could not be
easily detected unless they cause changes to the invar-
iant residues such as cysteine and tryptophan which
Figure 1 The percentage values of accurate and erroneous reads with different types of errors observed in antibodies #1-4. Antibody
#1 was sequenced twice as two independent repeat runs, 1 and 2.
Table 2 The consequence of 454 antibody sequencing
errors affecting the functionality of antibodies as
determined by IMGT/HighV-QUEST using sequence data
obtained from the two repeat 454 runs, 1 and 2
Productive 65.8 (16.1)a 68 (23)a
Unproductive 13.7 5.3
Stop codon 3.7 3.1
No rearrangement 0.6 0.5
Functionality Run 1 (%) Run 2 (%)
Productive 65.8 (16.1)a 68 (23)a
aThe percentage value of additional productive sequences recovered from the
pool of unproductive sequences by correcting the errors due to mainly
insertions.
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Figure 2 (a), (b) Distribution of insertion errors and involvement of different types nucleotides, G, C, A and T, observed at the V-
regions of antibody sequences from the two repeat 454 sequencing runs of antibody #1, which were detected and corrected by
IMGT/HighV-QUEST analysis tool.
Table 3 Insertion/deletion occurred in multiple reads mostly at homopolymeric regions of 2-3 nucleotide length as
well as at the random sites, for example, shown for run 1 of control antibody #1
Number of Sequences Homopolymeric region? Description of variation
6 sequences yes: 3G in place of 4 1 deletion
7 sequences yes: 4A in place of 3 1 insertion
8 sequences yes: 4T in place of 3 1 insertion
9 sequences yes: 4G in place of 2; no: 1 random G 2 + 1 insertion
11 sequences yes: 3G in place of 4 1 deletion
21 sequences yes: 4G in place of 3 1 insertion
22 sequences yes: 4G in place of 3 1 insertion
28 sequences no 1 deletion
31 sequences yes: 4C in place of 3 1 insertion
32 sequences yes: 3G in place of 2; no: 1 random G 1 + 1 insertion
42 sequences yes: 3G in place of 2 1 insertion
49 sequences no 1 deletion
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cases. Similarly, mixed variants were identified to have 2
or more changes involving different error types at a rate
of ~10% which, with the exception of insertions or dele-
tions, would have been difficult to detect and rectify by
post-computational processing.
Conclusions
Our findings indicate that 454 antibody sequencing pro-
duces about 60% accurate reads which could routinely be
improved above 80% by correcting insertions/deletions
occurring at homopolymer sites as well as random sites,
if represented by multiple reads and resulting in frame-
shifts, stop codons or modification of conserved residues.
W en o t e dt h a to t h e rt y p e so fe r r o r sc a u s e db ye r r o r s
involving 2 or more nucleotide changes might be challen-
ging; however, the use of post-processing methods such
as IMGT V-QUEST and other antibody-specific algo-
rithms to detect and rectify the errors to be developed
might improve the accuracy up to 90-95%. The randomly
occurring single nucleotide substitution errors account-
ing for 4-8% of the total reads as observed in run 1 and 2
of the larger data sets of control antibodies caused repla-
cement mutations that in many instances can not be
detected. These replacement errors may contribute to
the anticipated residual errors after the post-sequencing
error correction. Therefore, this type of errors could
potentially lead to false discovery of novel variants or
diversity unless verified with repeated runs or observed
in multiple clonally-related sequences. We suggest that
only those single nucleotide substitutions affecting the
invariant residues of the highly-conserved frameworks as
well as those residues at the complementarity determin-
ing regions that are conserved among the alleles and
(a)
(b)
Figure 3 (a), (b) The nucleotide composition analysis showing compositional differences in A, G, T and C (dA, dG, dT and dC) resulting
from insertion, deletion or substitution or by combination as observed in erroneous sequence reads, respectively, from Run 1 and 2
of antibody #1. Compositional differences are denoted by numeric values with “+” sign for overrepresentation and “-” sign for
underrepresentation at the vertical axis and the total number of recurring erroneous reads in percent at the horizontal axis.
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may be detected and corrected. These results could be
useful for identification and correction of 454 antibody
sequencing errors.
Methods
We used primers that were synthesized to include the
Roche A and B adaptor sequences along with target ampli-
fication sequences: ControlF- 5’-CCATCTCATCCCT
GCGTGTCTCCGACTCAGGCCACCAGCCATGGCC-3’
(sense primer) and HR2:5’-/5BioTEG/- CCTATCCCCT
GTGTGCCTTGGCAGTCTCAGGTCACAAGATTTG
GGCTCAAC -3’ (antisense primer) where 5BioTEG is a
5’-biotin-TEG moiety conjugated to the 5’ end of the pri-
mer. The gene fragments were PCR amplified through 12
cycles and other details were followed according to the
Roche 454 sequencing technical bulletin. Six different
DNA samples encoding for antibody heavy chains of dif-
ferent lengths of known sequences (see additional file 4
for sequences in FASTA format) were prepared at 3-fold
serial dilution and subjected to pyrosequencing using the
Roche/454 Genome Sequencer FLX. The numbers of
molecules in antibody #1 were empirically estimated based
on the content of DNA and concentration which was
approximately set to be 100. The numbers of molecules
present in the remaining antibodies were calculated by
taking into account of the 3-fold serial dilution. The 454
sequence data were trimmed for quality and only full-
length sequences covering the entire antibody variable
domain, FV region consisting all three complementarity
determining regions (CDRs) along with frameworks (FRs),
were retained (see additional files 5 and 6 for sequences in
FASTA format). Sequence identities were calculated based
on the pairwise alignment for each of 454 antibody
sequence against pertinent known DNA sequences using
local BLAST implemented in BioEdit v7.0.9 [9] with addi-
tional parameters, -G-1 -q-1 -r2. The BLAST output data
comprising the start and end points of query and subject,
and the number of mismatches including or excluding
gaps were used to determine the different types of errors
introduced during 454 pyrosequencing of antibodies. The
IMGT/HighV-QUEST analysis tool [10] was extensively
used to analyze 454 antibody sequence data for (i) locating
the insertion and deletion errors along the antibody vari-
able domain, (ii) identifying the consequences of such
errors including the number of productive and unproduc-
tive genes, stop codons and no rearrangements, and (iii)
correcting the antibody sequence errors which can be
achieved by selecting the option “search for insertions
and/or deletions” of advanced parameters available in the
tool. The output results were stored in CSV files contain-
ing functionality information, list of insertion and deletion
errors, and DNA as well as translated amino acid
sequences after applying the appropriate sequence correc-
tions. The algorithm and method implementation in
IMGT/HighV-QUEST tool for determining the antibody
functionality and correcting the antibody sequence errors
were described previously [11]. Briefly, the frequencies of
productive and unproductive sequences are calculated
based on the absence of stop codons with in-frame junc-
tions and stop codons with or without out-of-frame junc-
tions, respectively. For correcting the antibody sequence
errors, the IMGT tool uses two alignment steps (Smith
and Waterman algorithm [12]) comparing the user
sequence and the closest V genes and alleles in the data-
base. This would reveal the frameshifts caused by sequen-
cing errors to be fixed. First, if insertions are detected,
they are excluded from the user sequence as they are not
compatible with IMGT numbering and their locations are
identified. If deletions are detected, gaps are introduced in
the user sequence to restore the IMGT numbering. After
insertion and/or deletion detection steps, the identification
of V gene and allele are performed again and corrected
sequences are provided. Also, we computed the nucleotide
compositions for all reads from two sequencing runs of
antibody #1. Statistical calculations were carried out using
SAS JMP9
® statistical software (SAS Institute, Cary, NC)
as well as Excel macros using the results as obtained from
the BLAST and IMGT/HighV-QUEST. Graphical plots
were made using Microsoft Excel 2010.
Additional material
Additional file 1: 454 antibody sequencing errors observed in six
antibodies #1-6. The percentage values of accurate reads and erroneous
reads with which types of errors, such as insertion, deletion, substitution
and variants with 2 and more nucleotide changes were calculated from
454 sequence data of the six antibodies.
Additional file 2: Multiple sequence alignment highlighting the
location of insertion/deletion errors. The location of insertion/deletion
errors at homopolymeric regions of 2-3 nucleotide length as well as
random sites of multiple reads from run 1 of control antibody #1 is
shown by multiple sequence alignment of erroneous sequences along
with the control antibody #1.
Additional file 3: Multiple sequence alignment highlighting the
distribution of substitution errors. The distribution of substitution
errors resulting into replacement mutations (amino acids in single-letter
codes) and stop codons (marked with X) observed from run 1 and 2 of
control antibody 1, were shown in (a) and (b) respectively.
Additional file 4: FASTA file of the six antibodies #1-6. The
sequences of six clonally-related antibodies which are known from the
standard Sanger sequencing are given in the FASTA file.
Additional file 5: FASTA file containing 454 sequence data of six
antibodies #1-6 (sequences of antibody #1 correspond to
run 1 of antibody #1). 454 sequencing data derived from the
six control antibodies at different concentrations as mentioned in
Table 1.
Additional file 6: FASTA file containing 454 sequence data of run
2 of antibody #1. 454 sequencing data derived from the six control
antibodies at different concentrations as mentioned in Table 1.
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